Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin - Cadila Pharmaceuticals

Drug Profile

Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin - Cadila Pharmaceuticals

Alternative Names: Polypill - Cadila Pharmaceuticals

Latest Information Update: 30 Jan 2014

Price : $50

At a glance

  • Originator Cadila Pharmaceuticals
  • Class Antihyperlipidaemics; Antihypertensives; Antiplatelets; Benzothiadiazines; Heterocyclic bicyclo compounds; Ischaemic heart disorder therapies; Naphthalenes; Propanolamines; Salicylates; Small molecules
  • Mechanism of Action ACE inhibitors; Beta 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; HMG-CoA reductase inhibitors; Platelet aggregation inhibitors; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cardiovascular disorders; Coronary disorders; Stroke

Most Recent Events

  • 30 Jan 2014 Launched for Cardiovascular disorders and Stroke (primary prevention) in India (PO) before January 2014
  • 30 Jan 2014 Hydrochlorothiazide/atenolol/ramipril/simvastatin/aspirin - Cadila Pharmaceuticals is available for licensing in World as of 12 Apr 2009.
  • 01 Jun 2012 Phase-III clinical trials in Cardiovascular disorders (primary prevention) in India (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top